Watch for the End-of-Phase 2 meeting with the FDA and subsequent regulatory alignment, which will determine the Phase 3 design and timeline. Additional data presentations at NANETS (Nov 5) and ENA Symposium (Nov 20) may provide further efficacy and safety details. The clean safety profile and dose-response trend support advancement, but Phase 3 execution risk and the need for regulatory agreement remain key catalysts.
Price Chart
Executive Summary
Perspective Therapeutics reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET (bamzireotide navoxetan) in SSTR2-expressing neuroendocrine tumors at ESMO 2026. The data show a 50% objective response rate in the highest dose cohort (Cohort 3, 6.0 mCi), 95% disease control rate, 72% progression-free survival at 18 months, and no dose-limiting toxicities or treatment-related discontinuations. The company aims to complete Phase 3 site start-up preparations around year-end 2026 and expects to initiate a Phase 3 trial in 2027.
Key Facts
- ORR of 50% (10/20) in Cohort 3 (6.0 mCi) and 33% (15/46) in Cohort 2 (5.0 mCi), including unconfirmed responses
- Disease control rate of 95% in Cohort 3 and 89% in Cohort 2
- PFS rate of 72% at 18 months across all cohorts (n=68)
- No dose-limiting toxicities, no Grade 4/5 TEAEs, no treatment-related discontinuations
- Only 29% of patients (20/68) had any Grade 3 TEAE; no myelodysplastic syndrome or dysphagia reported
- Company aims to complete Phase 3 site start-up preparations around year-end 2026, with Phase 3 initiation expected in 2027
- Data presented as rapid oral presentation at ESMO Congress 2026 (Oct 23-27, Madrid)
Financial Impact
No financial data in filing; pre-revenue clinical-stage biotech. Positive clinical data supports pipeline valuation and potential partnership/licensing optionality.
Risk Factors
- Phase 3 trial may not replicate Phase 1/2a efficacy or safety results
- FDA may not agree with proposed Phase 3 development plan, delaying initiation beyond 2027
- Competition from approved SSTR2-targeted radiopharmaceuticals (e.g., Lutathera) and other alpha-emitter programs
- Manufacturing scale-up and supply chain for 212Pb-based therapies remain unproven at commercial scale
- Cash runway and need for additional financing to complete Phase 3 development
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-429770 |
| Document: catx-20261023.htm | 0001193125-26-429770 |
| Document: catx-ex99_2.htm | 0001193125-26-429770 |
| Document: 0001193125-26-429770-index-headers.html | 0001193125-26-429770 |
| Document: 0001193125-26-429770-index.html | 0001193125-26-429770 |
| Document: 0001193125-26-429770.txt | 0001193125-26-429770 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 19d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers